This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burnier, M. Articles by Brunner, H. R. Search for Related Content PubMed PubMed Citation Articles by Burnier, M. Articles by Brunner, H. R.

(Hypertension. 1995;25:602-609.)
© 1995 American Heart Association, Inc.

Articles

Short-term and Sustained Renal Effects of Angiotensin II Receptor Blockade in Healthy Subjects

Michel Burnier; Michael Hagman; Jurg Nussberger; Jérôme Biollaz; Catherine Armagnac; Rémi Brouard; Bernard Waeber; Hans R. Brunner

From the Division of Hypertension and Cardiovascular Research Group, Lausanne, Switzerland (M.B., M.H., J.N., J.B., B.W., H.R.B.) and Sanofi Recherche, Montpellier, France (C.A., R.B.).

Abstract We investigated the short-term and sustained hormonal and renal effects of angiotensin II (Ang II) receptor blockade in normotensive healthy volunteers. Twenty-four subjects maintained on a fixed sodium diet were randomized to receive for 8 days a placebo or 10 or 50 mg doses of the Ang II antagonist irbesartan (SR 47436, BMS 186295) according to a double-blind, parallel group design. Plasma renin activity, plasma immunoreactive Ang II and aldosterone levels, blood pressure, renal hemodynamics, and urinary electrolyte excretion were measured for 8 hours after the first and eighth administration of each dose of irbesartan or placebo. Ang II receptor blockade with irbesartan induced a dose-dependent compensatory increase in plasma renin activity and plasma angiotensin levels and a significant decrease in plasma aldosterone levels. The compensatory rise in plasma renin activity and Ang II levels was more pronounced on day 8, reflecting a long duration of the blocking effect of irbesartan. Irbesartan induced small changes in blood pressure and did not significantly modify renal blood flow and glomerular filtration rate. However, a significant decrease in filtration fraction was observed during receptor blockade on days 1 and 8. The tubular effects of irbesartan were characterized by a dose-dependent increase in sodium and chloride excretions. Interestingly, the cumulative natriuretic response to Ang II receptor blockade was similar on days 1 and 8, suggesting that in these subjects, renal Ang II receptors are not blocked over 24 hours during repeated administration even though this antagonist has a long duration of action (t_1/2 of 15 to 17 hours). Irbesartan had no significant effect on urinary potassium and uric acid excretions on days 1 and 8. Together, these results demonstrate that in healthy subjects the Ang II receptor antagonist irbesartan decreases filtration fraction and promotes urinary sodium excretion without affecting urinary uric acid excretion and that these renal hemodynamic and tubular effects are maintained during a repeated 8-day administration.

Key Words: receptors, angiotensin • angiotensin II • renal circulation • natriuresis • uric acid

This article has been cited by other articles:

				M. Salcedo-Alejos, F. Banda-Espinoza, M. Rodriguez-Moran, and F. Guerrero-Romero Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2120 - 2125. [Abstract] [Full Text] [PDF]

				M. Burnier Angiotensin II Type 1 Receptor Blockers Circulation, February 13, 2001; 103(6): 904 - 912. [Full Text] [PDF]

				N Girgrah, P Liu, J Collier, L Blendis, and F Wong Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis Gut, January 1, 2000; 46(1): 114 - 120. [Abstract] [Full Text] [PDF]

				J. V. Gainer, J. D. Morrow, A. Loveland, D. J. King, and N. J. Brown Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting-Enzyme Inhibitor in Normotensive and Hypertensive Subjects N. Engl. J. Med., October 29, 1998; 339(18): 1285 - 1292. [Abstract] [Full Text] [PDF]

				D. A. Price, J. M. De'Oliveira, N. D. L. Fisher, and N. K. Hollenberg Renal Hemodynamic Response to an Angiotensin II Antagonist, Eprosartan, in Healthy Men Hypertension, August 1, 1997; 30(2): 240 - 246. [Abstract] [Full Text]

				N. K. Hollenberg and N. D. L. Fisher Renal Circulation and Blockade of the Renin-Angiotensin System : Is Angiotensin-Converting Enzyme Inhibition the Last Word? Hypertension, October 1, 1995; 26(4): 602 - 609. [Abstract] [Full Text]